Aim immunotech provides summary of ampligen® data supporting synergistic potential with checkpoint blockade therapies

Ampligen has demonstrated in pre-clinical and now human clinical studies a potential to enhance efficacy of pd-1 and/or pd-l1 checkpoint inhibitors

AIM Ratings Summary

AIM Quant Ranking